Physicians

Department / Division
Medicine / Medicine - Oncology

Address
DUMC 3233
Durham, NC 27710

Appointment Telephone
919-668-6688

Office Telephone
919-681-3480

Fax Telephone
919-613-5228

Training

• MD, Yale University School of Medicine (Connecticut), 1990

Residency

• Internal Medicine, University of Washington Medical Center, 1990-1993

Fellowship

• Hematology/Oncology, Duke University Medical Center, 1993-1996

Other Training

• MHS, Duke University Medical Center, 2000

Clinical Interests
Gastrointestinal malignancies, hepatic tumors, immunotherapy, melanoma

Research Interests
We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma.  These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.

Our current clinical trials include phase I and II studies of immunotherapy for:  patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.

Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Advanced Liquid Logic, Inc.
• Amgen, Inc.
• Bayer
• Bristol-Myers Squibb
• Eisai, Inc.
• Etubics Corporation
• Genentech, Inc (Roche Holding)
• Genomic Health, Inc.
• GlobeImmune, Inc.
• Novartis
• Onyx
• Pfizer Inc.
• Prometheus Laboratories Inc.
• Roche
• Sanofi-Aventis

Representative Publications
Morse MA, Alvarez Secord A, Blackwell KL, Hobeika A, Sinnathamby G, Osada T, Hafner J, Philip M, Clay TM, Lyerly HK, Philip R. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T cell responses against breast and ovarian cancer. Clin Cancer Res. 2011 Feb 7. (2011) Abstract

Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, Niedzwiecki D, Devi GR, Burnett BK, Clay TM, Smith J, Lyerly HK. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest. 2010 Sep 1;120(9):3234-41. (2010) Abstract

Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, Lyerly HK, Clay TM. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. Int J Cancer. 2010 Jun 15;126(12):2893-903. (2010) Abstract

Osada T, Hsu D, Hammond S, Hobeika A, Devi G, Clay TM, Lyerly HK, Morse MA. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer. 2010 Jan 5;102(1):124-33. (2010) Abstract

Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O, Morse MA. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med. 2009;7:68. (2009) Abstract

Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood. 2008 Aug 1;112(3):610-8. (2008) Abstract

Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, Hurwitz HI, Dev I, Nixon AB, Lyerly HK, Clay T, Morse MA. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother. 2008 Aug;57(8):1115-24. (2008) Abstract

Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, Anders C, Devi GR, Lyerly HK, Clay TM. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med. 2007;5:42. (2007) Abstract

Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother. 2006 Sep;55(9):1122-31. (2006) Abstract

Hobeika AC, Morse MA, Osada T, Ghanayem M, Niedzwiecki D, Barrier R, Lyerly HK, Clay TM. Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother. 2005 Jan-Feb;28(1):63-72. (2005) Abstract

Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res. 2005 Apr 15;11(8):3017-24. (2005) Abstract

Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB, Lyerly HK. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005 Feb 21;3(1):9. (2005) Abstract

Bunce CJ, Morse MA. A need for effective adjuvants. Curr Opin Mol Ther. 2003 Feb;5(1):8-9. (2003) Abstract

Morse MA, Clay TM, Colling K, Hobeika A, Grabstein K, Cheever MA, Lyerly HK. HER2 Dendritic Cell Vaccines. Clin Breast Cancer. 2003 Feb;3 Suppl 4:S164-72. (2003) Abstract

Mosca PJ, Hobeika AC, Colling K, Clay TM, Thomas EK, Caron D, Lyerly HK, Morse MA. Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol. 2002 Sep;72(3):546-53. (2002) Abstract

Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res. 2001 May;7(5):1127-35. (2001) Abstract